Published in Food and Drug Law Weekly, August 25th, 2006
Avalon will use its proprietary AvalonRx platform to discover new active compounds in screens against selected targets and target pathways. ChemDiv will provide Avalon access to its Discovery outSource services platform, including the world's largest commercially available chemical library, as well as medicinal and synthetic chemistry for the discovery and development of new active compounds. Avalon and ChemDiv will share in the costs of development and the value of any lead candidate resulting from their...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Food and Drug Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.